CN111132697A - 包含抗bst-1抗体和胞苷类似物的药物组合 - Google Patents

包含抗bst-1抗体和胞苷类似物的药物组合 Download PDF

Info

Publication number
CN111132697A
CN111132697A CN201880060959.0A CN201880060959A CN111132697A CN 111132697 A CN111132697 A CN 111132697A CN 201880060959 A CN201880060959 A CN 201880060959A CN 111132697 A CN111132697 A CN 111132697A
Authority
CN
China
Prior art keywords
antibody
antibodies
cancer
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880060959.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·西蒙耐利
A·贝拉卡尼
M·比纳其
D·贝拉罗萨
C·卡利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Publication of CN111132697A publication Critical patent/CN111132697A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201880060959.0A 2017-07-21 2018-07-20 包含抗bst-1抗体和胞苷类似物的药物组合 Pending CN111132697A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP1711785.4 2017-07-21
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies
PCT/EP2018/069768 WO2019016371A1 (en) 2017-07-21 2018-07-20 PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG

Publications (1)

Publication Number Publication Date
CN111132697A true CN111132697A (zh) 2020-05-08

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880060959.0A Pending CN111132697A (zh) 2017-07-21 2018-07-20 包含抗bst-1抗体和胞苷类似物的药物组合

Country Status (22)

Country Link
US (1) US20200231694A1 (https=)
EP (1) EP3655033A1 (https=)
JP (1) JP2020527594A (https=)
KR (1) KR20200032162A (https=)
CN (1) CN111132697A (https=)
AR (1) AR112460A1 (https=)
AU (1) AU2018303241A1 (https=)
BR (1) BR112020001320A2 (https=)
CA (1) CA3070264A1 (https=)
CL (1) CL2020000175A1 (https=)
CO (1) CO2020001792A2 (https=)
EA (1) EA202090333A1 (https=)
GB (1) GB201711785D0 (https=)
IL (1) IL272096A (https=)
MA (1) MA49627A (https=)
MX (1) MX2020000752A (https=)
PH (1) PH12020550024A1 (https=)
SG (1) SG11202000390TA (https=)
TW (1) TW201907952A (https=)
UY (1) UY37815A (https=)
WO (1) WO2019016371A1 (https=)
ZA (1) ZA202000881B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236143A (zh) * 2018-06-14 2021-01-15 柏林化学股份公司 医药组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066568A2 (de) * 2004-12-23 2006-06-29 Tegenero Ag Monokonale agonistische anti-ctla-4 antikörper
WO2013003625A2 (en) * 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Antibodies
CN111971091A (zh) * 2018-04-13 2020-11-20 柏林化学股份公司 预防或治疗骨髓发育不良综合征的抗bst1抗体
CN114555123A (zh) * 2019-10-18 2022-05-27 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066568A2 (de) * 2004-12-23 2006-06-29 Tegenero Ag Monokonale agonistische anti-ctla-4 antikörper
WO2013003625A2 (en) * 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Antibodies
CN103649121A (zh) * 2011-06-28 2014-03-19 牛津生物疗法有限公司 针对adp-核糖基环化酶2的抗体
CN111971091A (zh) * 2018-04-13 2020-11-20 柏林化学股份公司 预防或治疗骨髓发育不良综合征的抗bst1抗体
CN114555123A (zh) * 2019-10-18 2022-05-27 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTINA KRUPKA 等: "Target CD157 in AML using a novel，Targeting CD157 in AML using a novel, Fc-engineered antibody construct" *
SUMITHIRA VASU 等: "Decitabine enhances anti-CD33 monoclonal antibody BI 835858-mediated natural killer ADCC against AML blasts" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236143A (zh) * 2018-06-14 2021-01-15 柏林化学股份公司 医药组合

Also Published As

Publication number Publication date
GB201711785D0 (en) 2017-09-06
SG11202000390TA (en) 2020-02-27
ZA202000881B (en) 2021-08-25
BR112020001320A2 (pt) 2020-08-11
MX2020000752A (es) 2020-08-17
AR112460A1 (es) 2019-10-30
EA202090333A1 (ru) 2020-05-06
IL272096A (en) 2020-03-31
WO2019016371A1 (en) 2019-01-24
CL2020000175A1 (es) 2020-06-12
TW201907952A (zh) 2019-03-01
EP3655033A1 (en) 2020-05-27
AU2018303241A1 (en) 2020-02-20
UY37815A (es) 2019-02-28
CO2020001792A2 (es) 2020-07-31
CA3070264A1 (en) 2019-01-24
MA49627A (fr) 2020-05-27
US20200231694A1 (en) 2020-07-23
PH12020550024A1 (en) 2021-02-15
KR20200032162A (ko) 2020-03-25
JP2020527594A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
JP2016047835A (ja) カドヘリン−１７に特異的な抗体
JP2014502955A (ja) 抗体
US10982005B2 (en) Antibodies to bone marrow stromal antigen 1
KR102058185B1 (ko) Adp-리보실 시클라제 2에 대한 항체
CN111971091A (zh) 预防或治疗骨髓发育不良综合征的抗bst1抗体
US20120231004A1 (en) Antibodies
CN111132697A (zh) 包含抗bst-1抗体和胞苷类似物的药物组合
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
RS56431B1 (sr) Antitela protiv adp-ribozil ciklaze 2
OA16799A (en) Antibodies to ADP-ribosyl cyclase 2.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200508